A few months ago, a 51-year-old patient named Daniel in Austin told his prescriber something I hear surprisingly often: "I've been on tesamorelin for ten weeks and I have no idea if it's working." His dose was 2 mg nightly. He felt slightly better sleep, maybe a little leaner. But he hadn't drawn a single lab since starting. His prescriber pulled an IGF-1 and it came back at 387 ng/mL, well above the age-adjusted normal ceiling of roughly 270 for a man his age. His fasting glucose had crept from 94 to 112. "I thought more was better," Daniel said. It's not. And without labs, he had no way of knowing.
That story captures the whole point of this article. Tesamorelin is a stabilized GHRH analog. It works. But it works on a dose-response curve with a safety window, and blood markers are the only way to see where you are on that curve. Compounded tesamorelin is prescribed off-label by licensed pharmacies; the branded version (Egrifta) is FDA-approved for HIV-associated lipodystrophy. Here's what to check, when to check it, and what the numbers actually mean.
The Baseline Panel You Actually Need
Before the first injection, get a snapshot of where you stand. This isn't optional. The minimum:
- IGF-1. Your primary scorecard for GH-axis activation.
- Fasting glucose and HbA1c. Because tesamorelin can nudge glucose up, you need to know your starting point.
- Lipid panel. Total cholesterol, LDL, HDL, triglycerides.
- Comprehensive metabolic panel (CMP). Liver enzymes, kidney function, electrolytes.
- CBC. General health screen.
- Blood pressure. Documented, not remembered.
Some prescribers tack on a thyroid panel (TSH, free T4) to rule out thyroid-driven GH-axis issues, sex hormones for a full picture, or hs-CRP as an inflammatory baseline. These are reasonable adds, not requirements.
And if visceral fat reduction is the goal, a body composition assessment (DEXA scan, bioelectrical impedance with VAT estimation, or even a simple tape measure around the waist) gives you something to compare against later. Without a baseline, your month-six DEXA is just a number floating in space.
IGF-1 Is the Whole Ballgame
If you only track one lab, this is the one.
IGF-1 is the direct downstream marker of growth hormone activity. It rises predictably with effective tesamorelin dosing. It's sensitive to dose changes. And it's the most validated safety signal: sustained elevation above the normal range correlates with increased risk.
The target is the upper half of the age-adjusted normal range. Not above it. Not "as high as possible." The upper half. Specific numbers depend on your lab's reference ranges and your age, but the principle holds.
Here's what the common scenarios look like:
- Baseline IGF-1 in the low or middle normal range and it rises into the upper half on standard dosing? Perfect. That's the intended response.
- Baseline IGF-1 already in the upper normal range? Proceed carefully. You may need a lower dose, or tesamorelin may not be the right fit at all.
- IGF-1 climbs above the normal ceiling on follow-up? Cut the dose. This is exactly the situation Daniel found himself in.
- IGF-1 doesn't budge despite weeks of consistent use? First, check injection technique and storage (reconstituted peptide left at room temperature loses potency fast). Then consider a dose increase if you started at 1 mg.
An optional early IGF-1 draw at weeks 4 to 6 can confirm you're responding before you wait the full three months. It's a small cost for useful early signal.
Glucose: The Lab Most People Underestimate
Growth hormone is counter-regulatory to insulin. That's not a side effect. It's physiology. Tesamorelin can raise fasting glucose modestly, and the clinical literature shows this consistently.
Get provider-reviewed GLP-1 therapy
Side effects are manageable with the right support. A licensed provider can adjust your dose when you need it.
Start Free Assessment →Fasting glucose at baseline and every three months. A bump of 5 to 10 mg/dL in a non-diabetic patient is common and generally not alarming. A jump from 95 to 118, like Daniel's? That needs attention.
HbA1c at the same intervals. This reflects three-month average glucose, so it's a smoother signal than a single fasting draw. Increases of 0.1 to 0.3 percentage points can occur. If you see a jump beyond 0.3 to 0.5 points, it's time to reassess.
Here's the thing about glucose: for healthy patients at standard doses, the effect is usually small. For prediabetic patients, it matters more. For diabetic patients, poorly controlled diabetes is a near-absolute contraindication to elective tesamorelin use. If diabetes is well-controlled, tesamorelin can be used with tighter monitoring and potential medication adjustment.
Lipids, CMP, and Blood Pressure (the Supporting Cast)
Tesamorelin tends to modestly improve lipid profiles. Triglycerides often drop. Total cholesterol may inch in the right direction. HDL and LDL changes are usually small. It's a nice secondary benefit, not the primary reason you're running lipids, but worth documenting. Check at baseline, three months, and six months.
The CMP (liver function, kidney function, electrolytes) is less about tesamorelin-specific effects, which are minimal on these markers, and more about general health surveillance. Baseline and six months is reasonable.
Blood pressure deserves its own mention. Modest BP changes have been reported with tesamorelin. If you have baseline hypertension, home monitoring during the first three months is smart. A decent home cuff costs $40 and pays for itself in useful data. Significant new hypertension or worsening of existing hypertension warrants a conversation with your prescriber, not just a shrug.
Body Composition: Measuring What You're Actually Trying to Change
If you're taking tesamorelin to reduce visceral fat (and most people are), you need objective measurement. Not just the mirror.
- DEXA scan is widely available and gives a comprehensive body composition picture.
- CT or MRI is the gold standard for visceral fat quantification but expensive and impractical for routine monitoring.
- Bioelectrical impedance with VAT estimation is less precise but accessible and affordable.
- Waist circumference is crude. It's also free and surprisingly useful for trending over time.
Baseline before therapy, follow-up at 12 to 26 weeks, then periodically. Think of it like weighing yourself on a scale that actually separates fat from lean mass.
A Practical Monitoring Calendar
Putting it all together:
- Baseline: Full panel (IGF-1, fasting glucose, HbA1c, lipids, CMP, CBC, blood pressure, body composition if available).
- Weeks 4 to 6 (optional): Early IGF-1 to confirm the drug is doing something.
- Month 3: IGF-1, fasting glucose, HbA1c, blood pressure.
- Month 6: Full panel repeat, including body composition.
- Annually thereafter: Full panel and body composition reassessment.
Patients with diabetes, hypertension, or other comorbidities may need closer intervals. Your prescriber sets the schedule; this is a reasonable framework.
When Labs Tell You to Change Course
The boring truth is that most adjustments come down to three scenarios:
Reduce the dose when IGF-1 climbs above the normal range, when fasting glucose rises meaningfully (especially into prediabetic territory from a normal baseline), when HbA1c trends up beyond 0.3 to 0.5 percentage points, when persistent edema or side effects suggest the dose is simply too high, or when significant new hypertension develops.
Increase the dose when IGF-1 hasn't risen meaningfully despite confirmed adherence and proper technique, when clinical response is insufficient at standard 2 mg (rare), or when a 1 mg starting dose has been adequately trialed without adequate response.
Stay the course when IGF-1 sits in the upper half of normal, glucose markers are stable, subjective response is satisfactory, and side effects are absent or minimal.
The most common mistake I see is people chasing an IGF-1 number they saw on a forum. Your number needs to be in your range for your age. Someone else's 320 may be their sweet spot and your danger zone.
What You Don't Need to Test
Direct GH measurement is pulse-dependent and unreliable for monitoring (your level changes minute to minute). A full pituitary function panel isn't needed unless there's a clinical reason. Frequent inflammatory markers and repeated thyroid testing add cost without value unless something was abnormal at baseline.
Home Tracking That Actually Helps
Between lab draws, you can self-monitor:
- Blood pressure with a home cuff
- Weight and waist circumference (weekly)
- Sleep quality (subjective but important)
- Energy and recovery from exercise
- Side effects, especially joint stiffness, water retention, or numbness in hands
Bring these notes to follow-up appointments. It takes two minutes to jot down and makes the visit twice as productive.
FAQ
What labs do I need before starting tesamorelin? At minimum: IGF-1, fasting glucose, HbA1c, lipid panel, CMP, and a documented blood pressure. Body composition assessment if available.
How often should I check labs? Standard schedule is baseline, 3 months, and 6 months, then annually. Patients with comorbidities may need closer monitoring.
What is the target IGF-1? Upper half of the age-adjusted normal range. Pushing above the normal range is not the goal and increases risk.
Will tesamorelin make me diabetic? In healthy patients at standard dose, glucose changes are usually small. In prediabetic patients, monitoring is more important. Tesamorelin can be used in well-controlled diabetes with closer monitoring and potential medication adjustment.
Do I need a DEXA scan? Useful but not required. Waist circumference and photos can provide adequate trending for many patients.
What if my IGF-1 doesn't rise at all? Confirm injection technique, reconstitution process, and peptide storage first. Cold chain breaks are the most common culprit. If everything checks out, discuss a dose increase with your prescriber.
Can I just track how I feel instead of running labs? You can, but you'd be flying blind. Subjective improvements are real, but they can't tell you whether your IGF-1 is dangerously elevated or your glucose is creeping into a problem zone. Labs and subjective tracking work together, not as substitutes.
---
Compounded tesamorelin is prescribed off-label for adults; the FDA-approved indication for the branded version (Egrifta) is HIV-associated lipodystrophy. Compounded tesamorelin is prepared by licensed pharmacies for individual patients based on a prescriber's clinical judgment. This article is educational only and does not constitute medical advice. Talk to a qualified clinician before starting any peptide therapy.
Related reading: Tesamorelin Dosage Protocols | Tesamorelin Side Effects Explained | Tesamorelin Benefits and Research | Tesamorelin Visceral Fat Protocol | Order Compounded Tesamorelin
---
Not FDA-approved. Compounded peptides are prepared by licensed 503A pharmacies for individual patients based on a prescriber's clinical judgment. FormBlends is not a medical practice. Individual results vary. Consult a licensed clinician before starting any peptide therapy.